INMD Add to watchlist
$15.15 +0.00 (+0.00%)
Pre-Market: $14.92 0.23 (-1.52%)
Last updated: Jul 15, 2026 09:17
52-Week Range
$14.92
$12.72 $14.92 $16.74

Fundamentals Overview

InMode Ltd. is in the middle of its 52-week range with low valuation, trading relatively flat today.

Valuation low

P/E 10.9 P/B 1.43 P/S 2.29

Intrinsic value (DCF)

+141% upside vs price

Profitability

Net margin 23.3%

Risk (Beta)

1.91 — higher vol

Earnings & growth

EPS $1.36 Rev -21% Profit -57.2% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 53% confidence Risk: High Volatility — Beta 1.91. Consider smaller position size due to higher beta.

Supporting (Buy):

DCF +141% upside vs price · Analyst grade: A+

Pressures (Sell):

Sentiment weakening (2 downgrades) · Beta 1.91 (elevated)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$857.61M
P/E (TTM)
10.94
EPS (TTM)
$1.36
Dividend Yield
N/A
52-Week Range
$12.72 - $16.74
Volume vs Avg
N/A
Beta
1.91

About

InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, s...
Sector: Healthcare
Headquarters: IL
Employees: 660
IPO Date: Aug 2019
Beta: 1.91 (More volatile than market)

Ratings & Grades at a Glance

Overall rating: A+. Recent institutional grades: majority downgrades. Current institutional positions: Hold: 14, Neutral: 5, Overweight: 11.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $35.96; current price is $14.92. That’s a +141% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 10.94
DCF value (model) $35.96 (141% upside)
PEG (TTM) N/A
P/B (TTM) 1.43
P/S (TTM) 2.29
P/FCF (TTM) 9.46
Liquidity & enterprise
Current Ratio (TTM) 8.8
Quick Ratio (TTM) 7.88
Cash Ratio (TTM) 5.1
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 23.27%
Gross margin (TTM) 77.84%
Operating margin (TTM) 21.31%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for INMD.

Analyst Sentiment at a Glance

A+ Sentiment Weakening
Hold 14Neutral 5Overweight 11
0 upgrades, 2 downgrades
Price Target Consensus
Current $14.92
Median $18.00
Consensus $18.00
Low consensus $17.00
High consensus $19.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Baird maintain Neutral Neutral 2026-05-07
Barclays maintain Overweight Overweight 2026-05-07
Canaccord Genuity maintain Hold Hold 2025-12-17
UBS maintain Neutral Neutral 2025-11-06
Needham maintain Hold Hold 2025-10-10
Canaccord Genuity maintain Hold Hold 2025-10-10
Needham maintain Hold Hold 2025-07-30
Barclays maintain Overweight Overweight 2025-07-30
Canaccord Genuity maintain Hold Hold 2025-07-11
Barclays maintain Overweight Overweight 2025-04-30
UBS maintain Neutral Neutral 2025-04-29
Canaccord Genuity maintain Hold Hold 2025-04-29
BTIG downgrade Buy Neutral 2025-04-29
Needham maintain Hold Hold 2025-04-28
Needham maintain Hold Hold 2025-04-14
Jefferies maintain Hold Hold 2025-04-14
Needham maintain Hold Hold 2025-04-09
Barclays maintain Overweight Overweight 2025-02-05
Needham maintain Hold Hold 2025-02-04
Barclays maintain Overweight Overweight 2025-01-09
Barclays maintain Overweight Overweight 2024-10-14
Jefferies downgrade Buy Hold 2024-07-23
Barclays maintain Overweight Overweight 2024-07-15
Canaccord Genuity maintain Hold Hold 2024-07-12
Barclays maintain Overweight Overweight 2024-04-12
Barclays maintain Overweight Overweight 2024-02-15
UBS maintain Neutral Neutral 2024-02-14
Barclays maintain Overweight Overweight 2024-01-18
Barclays maintain Overweight Overweight 2024-01-04
Canaccord Genuity maintain Hold Hold 2023-12-07